Syndax Pharmaceuticals Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Syndax Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syndax Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Syndax Pharmaceuticals.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Tuesday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.09. The company had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.50 million. Syndax Pharmaceuticals had a negative net margin of 5,645.68% and a negative trailing twelve-month return on equity of 45.08%.
View Syndax Pharmaceuticals' earnings history.

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SNDX shares have increased by 49.7% and is now trading at $17.65.
View which stocks have been most impacted by COVID-19.

9 brokers have issued twelve-month price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $28.75 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Syndax Pharmaceuticals include Sage Therapeutics (SAGE), Emergent BioSolutions (EBS), PTC Therapeutics (PTCT), Nektar Therapeutics (NKTR), Insmed (INSM), Dicerna Pharmaceuticals (DRNA), Taro Pharmaceutical Industries (TARO), Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), Axsome Therapeutics (AXSM), IGM Biosciences (IGMS) and Prestige Consumer Healthcare (PBH).
View all of SNDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.55%), Nantahala Capital Management LLC (4.15%), PFM Health Sciences LP (3.08%), Frazier Management LLC (2.98%), Ghost Tree Capital LLC (2.44%) and Point72 Asset Management L.P. (1.96%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Dennis Podlesak, Michael A Metzger, Michael L Meyers and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals.

SNDX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Acuta Capital Partners LLC, Ikarian Capital LLC, Point72 Asset Management L.P., Ghost Tree Capital LLC, 683 Capital Management LLC, Sphera Funds Management LTD., and BNP Paribas Arbitrage SA. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Michael A Metzger, and Peter Ordentlich.
View insider buying and selling activity for Syndax Pharmaceuticals or view top insider-selling stocks.

SNDX stock was purchased by a variety of institutional investors in the last quarter, including PFM Health Sciences LP, BlackRock Inc., Vivo Capital LLC, Price T Rowe Associates Inc. MD, Putnam Investments LLC, Nantahala Capital Management LLC, Citigroup Inc., and Rafferty Asset Management LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, Dennis Podlesak, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals or or view top insider-buying stocks.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNDX stock can currently be purchased for approximately $17.65.

Syndax Pharmaceuticals has a market capitalization of $851.59 million and generates $1.52 million in revenue each year. The company earns $-73,160,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

Syndax Pharmaceuticals employs 43 workers across the globe.

The official website for Syndax Pharmaceuticals is www.syndax.com.

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]